Pharmaceuticals Native Starch Global Market Report 2025

The pharmaceuticals native starch market size has grown strongly in recent years. It will grow from $5.65 billion in 2024 to $6.17 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth observed in the past can be linked to a higher demand for natural excipients, increased pharmaceutical production, a growing preference for biocompatible ingredients, the expansion of generic drug manufacturing, and greater regulatory backing for natural ingredients.

The pharmaceuticals native starch market size is expected to see strong growth in the next few years. It will grow to $8.69 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth expected in the forecast period is driven by rising investments in pharmaceutical innovation, a stronger focus on sustainable sourcing, the growing use of novel drug formulations, an increasing demand for clean-label pharmaceutical products, and higher healthcare spending in emerging markets. Key trends in the forecast period include advancements in starch processing technology, innovations in drug delivery systems, developments in bio-based pharmaceutical ingredients, ongoing research in plant-based excipients, and progress in solubility and stability solutions.

The growing prevalence of chronic diseases is expected to drive the expansion of the pharmaceutical native starch market in the coming years. Chronic diseases are long-term medical conditions that typically develop gradually and last for over a year. The rise in chronic diseases is largely due to an aging population, as older individuals are more prone to long-term health issues such as diabetes, cardiovascular diseases, arthritis, and cancer, which become more prevalent with age. Pharmaceutical native starch plays a significant role in managing chronic diseases by enhancing the stability of drug formulations, improving bioavailability, enabling controlled drug release, promoting patient adherence, and ultimately supporting the effectiveness and long-term management of chronic conditions. For example, in June 2024, the Australian Institute of Health and Welfare reported an increase in the death rate from chronic diseases, rising from 459 per 100,000 people in 2021 to 490 per 100,000 in 2022. As a result, the growing prevalence of chronic diseases is fueling the growth of the pharmaceutical native starch market.

Companies in the pharmaceutical native starch market are focusing on developing innovative products, such as plant-based textures, to improve drug formulation and patient compliance. Plant-based textures refer to the physical properties of plant-derived ingredients, such as thickness and gel strength, which help enhance the performance of native starch in pharmaceuticals by improving tablet binding, disintegration, and mouthfeel for more effective natural drug formulations. For example, in February 2024, Ingredion Incorporated, a U.S.-based food company, launched Novation Indulge 2940 starch, a clean-label texturizer designed to improve texture and stability in dairy and alternative dairy products. This innovative pharmaceutical native starch offers functional benefits that enhance drug formulation performance, bioavailability, and controlled release, while supporting the development of clean-label, sustainable products. NOVATION Indulge 2940 starch improves texture, stability, and consumer acceptance in both dairy and alternative dairy products, using clean-label, natural ingredients.

In September 2022, Roquette Frères, a France-based food company, acquired Crest Cellulose for an undisclosed sum. This acquisition aims to strengthen Roquette's position in the pharmaceutical excipients market by expanding its range of plant-based, pharmacopoeia-compliant solutions and meeting the growing demand for high-quality drug delivery ingredients, particularly in India and the Asia Pacific region. Crest Cellulose, an India-based manufacturer, specializes in producing pregelatinized starch and sodium starch glycolate.

Major players in the pharmaceuticals native starch market are Cargill Incorporated, Archer Daniels Midland Company, Ingredion Incorporated, Tereos SCA, Roquette Frères SA., AGRANA, Tate & Lyle Public Limited Company, Colorcon Inc., Grain Processing Corporation, Siam Modified Starch Co. Ltd., BENEO GmbH, Gulshan Polyols Ltd., SPAC Starch Products (India) Private Limited, Universal Starch-Chem Allied Ltd., Sanstar Biopolymers Ltd., Emsland Group, Hungrana Kft., Bluecraft Agro Pvt. Ltd., Visco Starch, and Shandong Liujia Pharmaceutical Excipient Co.Ltd.

North America was the largest region in the pharmaceuticals native starch market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharmaceuticals native starch report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pharmaceuticals native starch market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pharmaceutical native starch is a natural, unmodified starch sourced from plants such as corn, potato, wheat, or tapioca, and is used as an excipient in pharmaceutical formulations. It serves various purposes such as acting as a binder, disintegrant, or filler in tablets and capsules, playing a key role in regulating medication release, enhancing stability, and ensuring proper tablet formation, all without the need for chemical or physical alteration.

The primary types of pharmaceutical native starches include potato starch, corn starch, and others. Potato starch, a fine white powder extracted from potato tubers, is recognized for its smooth texture and superior binding capabilities, making it well-suited for pharmaceutical tablet formulations. It is available in various formulation types, including oral solids, liquids, topical products, injectables, and controlled-release formulations. Its versatility allows it to function as a texturizer, moisture-retaining agent, bulking agent, emulsifier, and film-former. It is commonly used as a binder, coating agent, disintegrant, filler, stabilizer, and thickener, serving a wide range of end-users such as pharmaceutical manufacturers, contract research organizations (CROs), contract manufacturing organizations (CMOs), research and development labs, academic institutions, and more.

The pharmaceuticals native starch market research report is one of a series of new reports that provides pharmaceuticals native starch market statistics, including pharmaceuticals native starch industry global market size, regional shares, competitors with a pharmaceuticals native starch market share, pharmaceuticals native starch market segments, market trends, and opportunities, and any further data you may need to thrive in the pharmaceuticals native starch industry. This pharmaceuticals native starch market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pharmaceuticals native starch market consists of sales of sorghum starch, barley starch, sweet potato starch, and arrowroot starch. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.